NCT05356897 2024-09-19Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyAcademic and Community Cancer Research UnitedPhase 2 Withdrawn
NCT03992456 2024-05-21Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerAcademic and Community Cancer Research UnitedPhase 2 Active not recruiting12 enrolled 16 charts